One thing we need to remember is after approval of Marqibo, TLON will most likely be acquired by big pharma so it wouldn't be wise for shareholders to sell their shares upon approval.
ltg---I think you have managed to condense the issue down to its essential points----existing drug (Vin)----patients with no recourse---Phase II showed success in extending life----the members of the ODAC panel that voted yes included all of the oncologists----is the FDA going to deny these patients a modified delivery method of the drug which is the SOC that may help them survive longer---I think not. It seems to me to have always been about this single issue---that's why WP is here--IMHO.